Be the first to review this item
Trimetazidine (Trimethazidinum) has anti-hypoxic effect.
Trimetazidine (INNS of Trimetazidine dihydrochloride) is a antianginal drug. Normalizes the energy metabolism of cells exposed to hypoxia or ischemia. Supports energy metabolism of the heart and neurosensory organs. Applied for the prevention of angina attacks in IHD, as well as in Meniere's disease, tinnitus, dizziness caused by disorders of cerebral circulation.
Directly affecting cardiomyocytes and neurons of the brain, optimizes their metabolism and function. Cytoprotective effect due to higher energy potential, activated oxidative decarboxylation and the rationalization of oxygen consumption (enhancement of aerobic glycolysis and blockade of fatty acid oxidation). Supports myocardial contractility, prevents a decrease in intracellular adenosine triphosphate (ATP) and phosphocreatine. Under acidosis normalizes the functioning of membrane ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, normalizes intracellular content of potassium ions. Reduces endocellular acidosis and the raised content of phosphates due to myocardial ischemia and reperfusion. It prevents the damaging effects of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, increases the duration of electrical potential, reduces the output of creatine phosphokinase from cells and the severity of ischemic myocardial damage.
Trimetazidin reduces the frequency of angina attacks, reduces the need for nitrate intake, after 2 weeks of admission increases exercise tolerance, decreases sharp fluctuations in blood pressure (BP). Reduces dizziness and tinnitus. When vascular pathology eye improves the functional activity of the retina.
After taking the drug inside Trimetazidine rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability is 90 %. The time to reach the maximum concentration in plasma-2 hours (maximum concentration after a single dose of 20 mg trimetazidina about 55 ng/ml). Easily permeates through gistogematicalkie barriers. The elimination half-life (T1/2) is 4.5-5 hours. Relationship with blood plasma proteins — 16 %. Excreted from the body by the kidneys (about 60% unchanged).
Do not use for relief of angina attacks. Not indicated for initial therapy of unstable angina or myocardial infarction. In the case of an attack of angina should be reviewed and adapted treatment.
Influence on the management of vehicles and machinery. Trimetazidine does not affect the ability to drive and perform work requiring high speed of psychomotor reactions.
Inside, during a meal.
The recommended dosing regimen - (40-60 mg) per day in 2-3 reception.
The course of treatment on the advice of the doctor.
Important notice- the outer box design may vary before prior notice!
Someone from the Hong Kong - just purchased the goods:
Kartalaks 60 capsules